Geriatrics

Top Story

ACIP recommends new shingles vaccine over Zostavax

ACIP recommends new shingles vaccine over Zostavax
October 25, 2017

Members of the Advisory Committee on Immunization Practices, or ACIP, voted 8-7 today to recommend the recently approved herpes zoster vaccine, Shingrix, over the only other FDA-approved vaccine, Zostavax.

Shingrix (GlaxoSmithKline) — a subunit adjuvanted vaccine that requires two doses — is now recommended for the prevention of herpes zoster, or shingles, in immunocompetent adults aged 50 years and older. ACIP members also voted 12-3 to recommend Shingrix for adults who previously received Zostavax (Merck), which is administered in a single dose.

FDA NewsPerspective

FDA approves shingles vaccine Shingrix

October 23, 2017
GlaxoSmithKline recently announced that the FDA has approved the company’s herpes zoster vaccine, Shingrix, for adults aged 50 years and older. The approval is…

Top five dermatology stories in July include psoriasis studies, FDA approval

July 31, 2017
Study results reporting that nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis was among the top read articles in…

Five recent developments in melanoma

July 12, 2017
Study findings that pathologists had lower levels of accuracy and reproducibility in diagnosing some melanomas when compared with other types of melanoma was among…
More Headlines »
Advertisement
Advertisement